RELMADA THERAPEUTICS, INC. Quarterly Nonoperating Income (Expense) in USD from Q3 2013 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Relmada Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2013 to Q2 2024.
  • Relmada Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $1.05M, a 45.2% increase year-over-year.
  • Relmada Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $4.57M, a 73.4% increase year-over-year.
  • Relmada Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $4.91M, a 16.8% increase from 2022.
  • Relmada Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $4.21M.
  • Relmada Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$48.3K, a 103% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $4.57M $1.05M +$327K +45.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $4.24M $1.16M -$672K -36.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $4.91M $1.66M +$906K +120% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-19
Q3 2023 $4M $691K +$1.37M Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $2.63M $724K -$4.85M -87% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $7.49M $1.83M +$3.28M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $4.21M $758K +$954K Oct 1, 2022 Dec 31, 2022 10-K 2024-03-19
Q3 2022 $3.25M -$682K -$729K -1537% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $3.98M $5.58M +$5.67M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$1.69M -$1.45M -$1.64M -862% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-05
Q4 2021 -$48.3K -$196K -$357K -221% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 $309K $47.4K -$234K -83.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $542K -$90.1K -$1.73M -105% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $2.27M $190K +$889K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $1.38M $161K +$124K +334% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-25
Q3 2020 $1.26M $281K +$243K +641% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $1.01M $1.64M +$1.63M +12400% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$611K -$699K -$715K -4485% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 $104K $37.1K +$3.69M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-24
Q3 2019 -$3.58M $37.9K +$1.01M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$4.59M $13.1K +$604K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 -$5.19M $15.9K +$668K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 -$5.86M -$3.65M -$3.68M -12586% Oct 1, 2018 Dec 31, 2018 10-Q 2019-02-13
Q3 2018 -$2.18M -$969K -$139K -16.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 -$2.04M -$591K Apr 1, 2018 Jun 30, 2018 10-KT 2020-03-26
Q1 2018 -$652K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 $29.2K Oct 1, 2017 Dec 31, 2017 10-Q 2019-02-13
Q3 2017 -$830K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q1 2015 $2.1M -$5.1M -70.8% Jan 1, 2015 Mar 31, 2015 10-Q 2015-05-15
Q4 2014 $9.84M +$9.95M Oct 1, 2014 Dec 31, 2014 10-Q 2015-02-13
Q3 2014 -$26.1M -$25M -2311% Jul 1, 2014 Sep 30, 2014 10-Q 2014-11-07
Q1 2014 $7.21M Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-15
Q4 2013 -$112K Oct 1, 2013 Dec 31, 2013 10-Q 2015-02-13
Q3 2013 -$1.08M Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.